

Junya Kanda

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5604237/publications.pdf>

Version: 2024-02-01

253
papers

3,757
citations

136940

32
h-index

189881

50
g-index

257
all docs

257
docs citations

257
times ranked

3782
citing authors

#	ARTICLE	IF	CITATIONS
1	Prognostic impact of CEBPA bZIP domain mutation in acute myeloid leukemia. Blood Advances, 2022, 6, 238-247.	5.2	61
2	Phase 2 study of axicabtagene ciloleucel in Japanese patients with relapsed or refractory large B-cell lymphoma. International Journal of Clinical Oncology, 2022, 27, 213-223.	2.2	10
3	Outcomes of third allogeneic hematopoietic stem cell transplantation in relapsed/refractory acute leukemia after a second transplantation. Bone Marrow Transplantation, 2022, 57, 43-50.	2.4	5
4	Development of a quantitative prediction model for peripheral blood stem cell collection yield in the plerixafor era. Cytotherapy, 2022, 24, 49-58.	0.7	5
5	The impact of GVHD on outcomes after adult single cord blood transplantation in European and Japanese populations. Bone Marrow Transplantation, 2022, 57, 57-64.	2.4	8
6	Impact of donor types on reduced-intensity conditioning allogeneic stem cell transplant for mature lymphoid malignancies. Bone Marrow Transplantation, 2022, 57, 243-251.	2.4	2
7	Comparing cord blood transplantation and matched related donor transplantation in non-remission acute myeloid leukemia. Leukemia, 2022, 36, 1132-1138.	7.2	16
8	HLA 3 antigen mismatched related peripheral blood stem cells transplantation using low dose antithymocyte globulin versus unrelated cord blood transplantation. American Journal of Hematology, 2022, 97, 311-321.	4.1	2
9	Human leukocyte antigen (HLA) haplotype matching in unrelated single HLA allele mismatch bone marrow transplantation. Bone Marrow Transplantation, 2022, 57, 407-415.	2.4	1
10	Evaluation of indices for predicting recovery of exercise tolerance in patients surviving allogeneic hematopoietic stem cell transplantation. Supportive Care in Cancer, 2022, 30, 4027-4034.	2.2	3
11	Deletion of Y chromosome before allogeneic hematopoietic stem cell transplantation in male recipients with female donors. Blood Advances, 2022, 6, 1895-1903.	5.2	5
12	Bortezomib-cyclophosphamide-dexamethasone induction/consolidation and bortezomib maintenance for transplant-eligible newly diagnosed multiple myeloma: phase 2 multicenter trial. Hematology, 2022, 27, 239-248.	1.5	0
13	Coexistence of HLA and KIR ligand mismatches as a risk factor for viral infection early after cord blood transplantation. Bone Marrow Transplantation, 2022, , .	2.4	2
14	Antithymocyte Globulin Potentially Could Overcome an Adverse Effect of Acute Graft-versus-Host Disease in Matched-Related Peripheral Blood Stem Cell Transplantation. Transplantation and Cellular Therapy, 2022, 28, 153.e1-153.e11.	1.2	2
15	Myeloablative Versus Reduced-Intensity Conditioning With Fludarabine/Busulfan for Myelodysplastic Syndrome: A Propensity Score-Matched Analysis. Transplantation and Cellular Therapy, 2022, 28, 323.e1-323.e9.	1.2	2
16	Feasibility of ovarian stimulation for fertility preservation during and after blinatumomab treatment for Ph-negative B-cell acute lymphoblastic leukemia. International Journal of Hematology, 2022, 116, 453-458.	1.6	1
17	Decision Analysis for Unrelated Bone Marrow Transplantation or Immediate Cord Blood Transplantation for Patients with Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia in First Complete Remission. Transplantation and Cellular Therapy, 2022, 28, 161.e1-161.e10.	1.2	1
18	Impact of HLA Epitope Matching on Outcomes After Unrelated Bone Marrow Transplantation. Frontiers in Immunology, 2022, 13, 811733.	4.8	2

#	ARTICLE	IF	CITATIONS
19	Autologous or allogeneic hematopoietic cell transplantation for relapsed or refractory PTCL-NOS or AITL. <i>Leukemia</i> , 2022, 36, 1361-1370.	7.2	5
20	Successful allogeneic bone marrow transplantation in a case of variant acute promyelocytic leukemia with ZBTB16-RARA. <i>Annals of Hematology</i> , 2022, 101, 1129-1132.	1.8	1
21	NPM1-mutation-based measurable residual disease assessment after completion of two courses of post-remission therapy is a valuable clinical predictor of the prognosis of acute myeloid leukemia. <i>International Journal of Hematology</i> , 2022, , 1.	1.6	2
22	Outcome of therapy-related myelodysplastic syndrome and oligoblastic acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation: A propensity score matched analysis. <i>Hematological Oncology</i> , 2022, 40, 752-762.	1.7	5
23	Establishment of a predictive model for GVHD-free, relapse-free survival after allogeneic HSCT using ensemble learning. <i>Blood Advances</i> , 2022, 6, 2618-2627.	5.2	12
24	Single Cord Blood Transplantation Versus HLA-Haploidentical-related Donor Transplantation Using Posttransplant Cyclophosphamide in Patients With Hematological Malignancies. <i>Transplantation</i> , 2022, 106, 1279-1287.	1.0	4
25	Current and future perspectives on cord blood transplantation. <i>Journal of Illusion</i> , 2022, 11, 101-107.	0.1	0
26	Comparison of the impact of two post-remission therapy regimens on cardiac events in acute myeloid leukemia patients undergoing allogeneic hematopoietic stem cell transplantation. <i>International Journal of Hematology</i> , 2022, , 1.	1.6	1
27	Addition and drug monitoring of mycophenolate mofetil for GVHD prophylaxis in unrelated bone marrow transplantation. <i>Bone Marrow Transplantation</i> , 2022, 57, 1198-1200.	2.4	1
28	Ideal Body Weight Is Useful For Predicting Neutrophil Engraftment and Platelet Recovery for Overweight and Obese Recipients in Single-Unit Cord Blood Transplantation. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 504.e1-504.e7.	1.2	1
29	Effect of Multiple HLA Locus Mismatches on Outcomes after Single Cord Blood Transplantation. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 398.e1-398.e9.	1.2	6
30	Overcoming minimal residual disease using intensified conditioning with medium-dose etoposide, cyclophosphamide and total body irradiation in allogeneic stem cell transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia in adults. <i>Cytotherapy</i> , 2022, 24, 954-961.	0.7	3
31	Relative hypercoagulation induced by suppressed fibrinolysis after tisagenlecleucel infusion in malignant lymphoma. <i>Blood Advances</i> , 2022, 6, 4216-4223.	5.2	4
32	Real-world effectiveness and safety analysis of carfilzomib+lenalidomide+dexamethasone and carfilzomib+dexamethasone in relapsed/refractory multiple myeloma: a multicenter retrospective analysis. <i>Therapeutic Advances in Hematology</i> , 2022, 13, 204062072211045.	2.5	6
33	Intramuscular Adipose Tissue Content Predicts Patient Outcomes after Allogeneic Hematopoietic Stem Cell Transplantation. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 602.e1-602.e7.	1.2	1
34	Advantages of peripheral blood stem cells from unrelated donors versus bone marrow transplants in outcomes of adult acute myeloid leukemia patients. <i>Cytotherapy</i> , 2022, 24, 1013-1025.	0.7	3
35	Portal vein thrombosis due to essential thrombocythemia with limited cutaneous systemic sclerosis. <i>Clinical Journal of Gastroenterology</i> , 2021, 14, 293-296.	0.8	1
36	Allogeneic stem cell transplantation for patients with aggressive NK-cell leukemia. <i>Bone Marrow Transplantation</i> , 2021, 56, 347-356.	2.4	9

#	ARTICLE	IF	CITATIONS
37	Detection of adenovirus hepatitis and acute liver failure in allogeneic hematopoietic stem cell transplant patients. <i>Transplant Infectious Disease</i> , 2021, 23, e13496.	1.7	21
38	Clinical Benefits of Preconditioning Intervention in Patients with Relapsed or Refractory Acute Myelogenous Leukemia Who Underwent Allogeneic Hematopoietic Cell Transplantation: A Kanto Study of Group for Cell Therapy Multicenter Analysis. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 70.e1-70.e8.	1.2	0
39	Predicting non-relapse mortality following allogeneic hematopoietic cell transplantation during first remission of acute myeloid leukemia. <i>Bone Marrow Transplantation</i> , 2021, 56, 387-394.	2.4	13
40	Reduced leukemia relapse through cytomegalovirus reactivation in killer cell immunoglobulin-like receptor-ligand-mismatched cord blood transplantation. <i>Bone Marrow Transplantation</i> , 2021, 56, 1352-1363.	2.4	7
41	Favorable Outcomes after Single Cord Blood Transplantation for Patients with High-Risk Hematologic Diseases: A Single-Institute Retrospective Analysis. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 495.e1-495.e9.	1.2	7
42	Definitive radiotherapy for secondary esophageal cancer after allogeneic hematopoietic stem cell transplantation. <i>International Cancer Conference Journal</i> , 2021, 10, 201-206.	0.5	2
43	Higher exercise tolerance early after allogeneic hematopoietic stem cell transplantation is the predictive marker for higher probability of later social reintegration. <i>Scientific Reports</i> , 2021, 11, 7190.	3.3	11
44	Multiple thrombosis during eltrombopag therapy. <i>ElHaem</i> , 2021, 2, 291-292.	1.0	0
45	Plateau is a prognostic factor of lenalidomide therapy for previously treated multiple myeloma. <i>Hematological Oncology</i> , 2021, 39, 349-357.	1.7	1
46	Does one model fit all? Predicting non-relapse mortality after allogeneic hematopoietic cell transplantation. <i>Bone Marrow Transplantation</i> , 2021, 56, 1720-1722.	2.4	1
47	Prognostic factors in salvage transplantation for graft failure following allogeneic hematopoietic stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2021, 56, 2183-2193.	2.4	3
48	Single Cord Blood Transplantation Versus Unmanipulated Haploidentical Transplantation for Adults with Acute Myeloid Leukemia in Complete Remission. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 334.e1-334.e11.	1.2	23
49	Allogeneic hematopoietic stem cell transplantation for adult patients with B-cell acute lymphoblastic leukemia with high hyperdiploidy: a retrospective nationwide study. <i>Leukemia and Lymphoma</i> , 2021, 62, 1-7.	1.3	0
50	Impact of the combination of donor age and HLA disparity on the outcomes of unrelated bone marrow transplantation. <i>Bone Marrow Transplantation</i> , 2021, 56, 2410-2422.	2.4	3
51	Differential Effect of Graft-versus-Host Disease on Survival in Acute Leukemia according to Donor Type. <i>Clinical Cancer Research</i> , 2021, 27, 4825-4835.	7.0	14
52	Analysis of factors associated with patient-reported physical functioning scores at discharge of allogeneic hematopoietic stem cell transplantation patients: a cross-sectional study. <i>Supportive Care in Cancer</i> , 2021, 29, 7569-7576.	2.2	4
53	Impact of conditioning intensity and regimen on transplant outcomes in patients with adult T-cell leukemia-lymphoma. <i>Bone Marrow Transplantation</i> , 2021, 56, 2964-2974.	2.4	4
54	Fludarabine/busulfan versus busulfan/cyclophosphamide as myeloablative conditioning for myelodysplastic syndrome: a propensity score-matched analysis. <i>Bone Marrow Transplantation</i> , 2021, 56, 3008-3015.	2.4	4

#	ARTICLE	IF	CITATIONS
55	Allogeneic Hematopoietic Cell Transplantation from Alternative Donors in Acute Myelogenous Leukemia: A Comparative Analysis. Transplantation and Cellular Therapy, 2021, 27, 1005.e1-1005.e8.	1.2	1
56	Syngeneic hematopoietic stem cell transplantation for acute myeloid leukemia: a propensity score-matched analysis. Blood Cancer Journal, 2021, 11, 159.	6.2	2
57	Impact of HLA disparity on the risk of overall mortality in patients with grade II-IV acute GVHD on behalf of the HLA Working Group of Japan Society for Hematopoietic Cell Transplantation. Bone Marrow Transplantation, 2021, 56, 2990-2996.	2.4	2
58	Altered effect of killer immunoglobulin-like receptor-ligand mismatch by graft versus host disease prophylaxis in cord blood transplantation. Bone Marrow Transplantation, 2021, 56, 3059-3067.	2.4	2
59	Outcomes of ixazomib/lenalidomide/dexamethasone for multiple myeloma: A multicenter retrospective analysis. European Journal of Haematology, 2021, 106, 555-562.	2.2	9
60	Outcome of allogeneic hematopoietic stem cell transplantation for follicular lymphoma relapsing after autologous transplantation: analysis of the Japan Society for Hematopoietic Cell Transplantation. Bone Marrow Transplantation, 2021, 56, 1462-1466.	2.4	4
61	Possible nosocomial transmission of virus-associated hemorrhagic cystitis after allogeneic hematopoietic stem cell transplantation. Annals of Hematology, 2021, 100, 753-761.	1.8	10
62	Identification of an asymptomatic Shwachman-Bodian-Diamond syndrome mutation in a patient with acute myeloid leukemia. International Journal of Hematology, 2021, , 1.	1.6	1
63	Significance of maintenance therapy after HDT/ASCT in symptomatic multiple myeloma: A multicenter retrospective analysis in Kansai Myeloma Forum. EJHaem, 2021, 2, 765-773.	1.0	0
64	Impact of event-free survival status after stem cell transplantation on subsequent survival of patients with lymphoma. Blood Advances, 2021, 5, 1412-1424.	5.2	1
65	Comparing Single Cord Blood Transplantation and Matched Related Donor Transplantation in Non-Remission Acute Myeloid Leukemia. Blood, 2021, 138, 1790-1790.	1.4	0
66	Single Cord Blood Transplantation Versus HLA-Haploidentical Related Donor Transplantation Using Post-Transplant Cyclophosphamide in Patients with Hematological Malignancies. Blood, 2021, 138, 2927-2927.	1.4	0
67	Comparison of Myeloablative Versus Reduced-Intensity Fludarabine/Busulfan Regimen in Patients with Myelodysplastic Syndrome Undergoing Allogeneic Hematopoietic Stem Cell Transplantation. Blood, 2021, 138, 3692-3692.	1.4	0
68	The First-in-Human Clinical Trial of iPSC-Derived Platelets (iPLAT1): Autologous Transfusion to an Aplastic Anemia Patient with Alloimmune Platelet Transfusion Refractoriness. Blood, 2021, 138, 351-351.	1.4	6
69	HLA-B Leader Dimorphism Impacts on Outcomes of HLA-Matched Related/Unrelated Transplantation: Analysis of the Japanese Society for Transplantation and Cellular Therapy. Blood, 2021, 138, 2919-2919.	1.4	1
70	Impact of Human Leukocyte Antigen Epitope Matching on Outcomes after Unrelated Bone Marrow Transplantation. Blood, 2021, 138, 3914-3914.	1.4	0
71	Allogeneic hematopoietic cell transplantation in patients with untreated acute myeloid leukemia: a KSGCT multicenter retrospective analysis. Bone Marrow Transplantation, 2020, 55, 1497-1501.	2.4	1
72	Effects of Haplotype Matching on Outcomes after Adult Single-Cord Blood Transplantation. Biology of Blood and Marrow Transplantation, 2020, 26, 509-518.	2.0	11

#	ARTICLE	IF	CITATIONS
73	Impact of Homozygous Conserved Extended HLA Haplotype on Single Cord Blood Transplantation: Lessons for Induced Pluripotent Stem Cell Banking and Transplantation in Allogeneic Settings. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 132-138.	2.0	11
74	Conditioning Intensity for Allogeneic Hematopoietic Cell Transplantation in Acute Myeloid Leukemia Patients with Poor-Prognosis Cytogenetics in First Complete Remission. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 463-471.	2.0	13
75	Time-Varying Effects of Graft Type on Outcomes for Patients with Acute Myeloid Leukemia Undergoing Allogeneic Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 307-315.	2.0	12
76	Prognostic factors for adult single cord blood transplantation among European and Japanese populations: the Eurocord/ALWP-EBMT and JSHCT/JDCHCT collaborative study. <i>Leukemia</i> , 2020, 34, 128-137.	7.2	36
77	Effect of the severity of acute graft-versus-host disease on physical function after allogeneic hematopoietic stem cell transplantation. <i>Supportive Care in Cancer</i> , 2020, 28, 3189-3196.	2.2	23
78	Increased Relapse Risk of Acute Lymphoid Leukemia in Homozygous HLA-C1 Patients after HLA-Matched Allogeneic Transplantation: A Japanese National Registry Study. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 431-437.	2.0	5
79	Impact of HLA Allele Mismatch at HLA-A, -B, -C, and -DRB1 in Single Cord Blood Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 519-528.	2.0	34
80	Improvement of early mortality in single-unit cord blood transplantation for Japanese adults from 1998 to 2017. <i>American Journal of Hematology</i> , 2020, 95, 343-353.	4.1	39
81	Updated Comparison of 7/8 HLA Allele-Matched Unrelated Bone Marrow Transplantation and Single-Unit Umbilical Cord Blood Transplantation as Alternative Donors in Adults with Acute Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 2105-2114.	2.0	17
82	Risk factors and appropriate therapeutic strategies for thrombotic microangiopathy after allogeneic HSCT. <i>Blood Advances</i> , 2020, 4, 3169-3179.	5.2	15
83	Impact of Donor Source on Allogeneic Hematopoietic Stem Cell Transplantation for Mature T Cell and Natural Killer Cell Neoplasms in the Kyoto Stem Cell Transplantation Group. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 2346-2358.	2.0	4
84	Retrospective analysis of plasmacytoma in Kansai Myeloma Forum Registry. <i>International Journal of Hematology</i> , 2020, 112, 666-673.	1.6	2
85	Effect of allogeneic HCT from unrelated donors in AML patients with intermediate- or poor-risk cytogenetics: a retrospective study from the Japanese Society for HCT. <i>Annals of Hematology</i> , 2020, 99, 2927-2937.	1.8	1
86	Retrospective multi-center study of Adolescent and Young Adult (AYA) Multiple Myeloma in Kansai Myeloma Forum registry. <i>International Journal of Hematology</i> , 2020, 112, 435-438.	1.6	3
87	Impact of HLA class I allele-level mismatch on viral infection within 100 days after cord blood transplantation. <i>Scientific Reports</i> , 2020, 10, 21150.	3.3	2
88	Indication and benefit of upfront hematopoietic stem cell transplantation for T-cell lymphoblastic lymphoma in the era of ALL-type induction therapies. <i>Scientific Reports</i> , 2020, 10, 21418.	3.3	6
89	Hematopoietic Stem Cell Transplantation From a Related Donor with Human Leukocyte Antigen 1-Antigen Mismatch in the Graft-Versus-Host Direction Using Low-dose Anti-thymocyte Globulin. <i>Cell Transplantation</i> , 2020, 29, 096368972097656.	2.5	6
90	Drug monitoring for mycophenolic acid in graft-versus-host disease prophylaxis in cord blood transplantation. <i>British Journal of Clinical Pharmacology</i> , 2020, 86, 2464-2472.	2.4	8

#	ARTICLE	IF	CITATIONS
91	The prognostic impact of FLT3-ITD, NPM1 and CEBPa in cytogenetically intermediate-risk AML after first relapse. <i>International Journal of Hematology</i> , 2020, 112, 200-209.	1.6	6
92	Effect of graft-versus-host disease on outcomes after pediatric single cord blood transplantation. <i>Bone Marrow Transplantation</i> , 2020, 55, 1430-1437.	2.4	9
93	Reduced-intensity stem cell transplantation for acute myeloid leukemia with fludarabine-based conditioning with intravenous busulfan versus melphalan. <i>Bone Marrow Transplantation</i> , 2020, 55, 1955-1965.	2.4	4
94	Wide availability of HLA â€œmatched or a few lociâ€œ mismatched donors in the graftâ€œvsâ€œ host direction among nonsibling firstâ€œdegree relatives. <i>Hla</i> , 2020, 95, 543-554.	0.6	1
95	Comparison of the outcomes after haploidentical and cord blood salvage transplantations for graft failure following allogeneic hematopoietic stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2020, 55, 1784-1795.	2.4	17
96	Outcomes and Prognostic Factors for Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia Who Underwent Allogeneic Hematopoietic Cell Transplantation: A KSGCT Multicenter Analysis. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 998-1004.	2.0	4
97	Influence of HLA 1â€œ3-locus mismatch and antithymocyte globulin administration in unrelated bone marrow transplantation. <i>Annals of Hematology</i> , 2020, 99, 1099-1110.	1.8	1
98	Hematopoietic cell infusionâ€œrelated adverse events in pediatric/small recipients in a prospective/multicenter study. <i>Transfusion</i> , 2020, 60, 1015-1023.	1.6	6
99	Favorable Effect of Cytomegalovirus Reactivation on Outcomes in Cord Blood Transplant and Its Differences Among Disease Risk or Type. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 1363-1370.	2.0	8
100	Heterogeneous impact of cytomegalovirus reactivation on nonrelapse mortality in hematopoietic stem cell transplantation. <i>Blood Advances</i> , 2020, 4, 1051-1061.	5.2	17
101	Lymphopenia at diagnosis predicts survival of patients with immunodeficiency-associated lymphoproliferative disorders. <i>Annals of Hematology</i> , 2020, 99, 1565-1573.	1.8	3
102	Outcome of Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Myelodysplastic/Myeloproliferative Neoplasms-Unclassifiable: A Retrospective Nationwide Study of the Japan Society for Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 1607-1611.	2.0	6
103	Comparison of reduced-intensity/toxicity conditioning regimens for umbilical cord blood transplantation for lymphoid malignancies. <i>Bone Marrow Transplantation</i> , 2020, 55, 2098-2108.	2.4	3
104	The Impact of Anti-Microbial Drug-Drug Interactions on Acute Kidney Injury after Allogeneic Hematopoietic Cell Transplantation. <i>Blood</i> , 2020, 136, 29-30.	1.4	1
105	Impact of graft-versus-host disease on relapse and survival after allogeneic stem cell transplantation for pediatric leukemia. <i>Bone Marrow Transplantation</i> , 2019, 54, 68-75.	2.4	49
106	Does an increased probability of graftâ€œvsâ€œ host disease improve the survival of patients with adult Tâ€œcell leukemiaâ€œlymphoma? A simulation analysis using a Markov model. <i>Advances in Cell and Gene Therapy</i> , 2019, 2, e56.	0.9	1
107	Significance of FLT3-tyrosine kinase domain mutation as a prognostic factor for acute myeloid leukemia. <i>International Journal of Hematology</i> , 2019, 110, 566-574.	1.6	18
108	Serum ferritin levels at diagnosis predict prognosis in patients with low blast count myelodysplastic syndromes. <i>International Journal of Hematology</i> , 2019, 110, 533-542.	1.6	6

#	ARTICLE	IF	CITATIONS
109	Outcomes of allogeneic stem cell transplantation for DLBCL: a multi-center study from the Kyoto Stem Cell Transplantation Group. <i>Annals of Hematology</i> , 2019, 98, 2815-2823.	1.8	11
110	Impact of High-Frequency HLA Haplotypes on Clinical Cytomegalovirus Reactivation in Allogeneic Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 2482-2489.	2.0	3
111	Impact of cumulative steroid dose on infectious diseases after allogeneic hematopoietic stem cell transplantation. <i>Transplant Infectious Disease</i> , 2019, 21, e13049.	1.7	4
112	Clinical significance of low-dose total body irradiation in HLA-mismatched reduced-intensity stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2019, 54, 1327-1336.	2.4	7
113	Effect of laminar air flow and building construction on aspergillosis in acute leukemia patients: a retrospective cohort study. <i>BMC Infectious Diseases</i> , 2019, 19, 38.	2.9	2
114	Allogeneic hematopoietic cell transplantation for patients with a history of multiple relapses of acute myeloid leukemia. <i>Annals of Hematology</i> , 2019, 98, 2179-2186.	1.8	8
115	ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR PATIENTS WITH AGGRESSIVE NATURAL KILLER CELL LEUKEMIA: A NATIONWIDE MULTICENTER ANALYSIS IN JAPAN. <i>Hematological Oncology</i> , 2019, 37, 479-480.	1.7	0
116	Prognostic index for patients with relapsed or refractory acute myeloid leukemia who underwent hematopoietic cell transplantation: a KSGCT multicenter analysis. <i>Leukemia</i> , 2019, 33, 2610-2618.	7.2	12
117	Guest Editorial: Are "alternative" stem cell sources still alternative in the new era?. <i>International Journal of Hematology</i> , 2019, 110, 20-21.	1.6	0
118	Unit selection for umbilical cord blood transplantation for adults with acute myeloid leukemia in complete remission: a Japanese experience. <i>Bone Marrow Transplantation</i> , 2019, 54, 1789-1798.	2.4	39
119	ABO blood type incompatibility lost the unfavorable impact on outcome in unrelated bone marrow transplantation. <i>Bone Marrow Transplantation</i> , 2019, 54, 1676-1685.	2.4	10
120	Short-term clinical outcomes after HLA 1-locus mismatched uPBSCT are similar to that after HLA-matched uPBSCT and uBMT. <i>International Journal of Hematology</i> , 2019, 109, 684-693.	1.6	3
121	Outcomes of second allogeneic haematopoietic stem cell transplantation in patients with relapse of myelodysplastic syndrome. <i>British Journal of Haematology</i> , 2019, 186, 86-90.	2.5	7
122	Cytomegalovirus reactivation is associated with increased mortality more than 100 days after allogeneic hematopoietic stem cell transplantation for adult T-cell leukemia/lymphoma. <i>American Journal of Hematology</i> , 2019, 94, E143-E146.	4.1	8
123	BM is preferred over PBSCs in transplantation from an HLA-matched related female donor to a male recipient. <i>Blood Advances</i> , 2019, 3, 1750-1760.	5.2	6
124	Haploidentical transplantation using low-dose alemtuzumab: Comparison with haploidentical transplantation using low-dose thymoglobulin. <i>European Journal of Haematology</i> , 2019, 102, 256-264.	2.2	14
125	HLA discrepancy between graft and host rather than that graft and first donor impact the second transplant outcome. <i>Haematologica</i> , 2019, 104, 1055-1061.	3.5	3
126	Effects of HLA mismatch on cytomegalovirus reactivation in cord blood transplantation. <i>Bone Marrow Transplantation</i> , 2019, 54, 1004-1012.	2.4	16

#	ARTICLE	IF	CITATIONS
127	Risk factors and timing of autologous stem cell transplantation for patients with peripheral T-cell lymphoma. <i>International Journal of Hematology</i> , 2019, 109, 175-186.	1.6	14
128	Prognostic impact of melphalan dose and total body irradiation use in patients with acute myeloid leukemia undergoing allogeneic stem cell transplantation with reduced-intensity conditioning. <i>Leukemia and Lymphoma</i> , 2019, 60, 1493-1502.	1.3	6
129	Lymphocyte Area Under the Curve as a Predictive Factor for Viral Infection after Allogeneic Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 587-593.	2.0	7
130	Upfront allogeneic hematopoietic cell transplantation (HCT) versus remission induction chemotherapy followed by allogeneic HCT for acute myeloid leukemia with multilineage dysplasia: A propensity score matched analysis. <i>American Journal of Hematology</i> , 2019, 94, 103-110.	4.1	8
131	Peripheral Blood versus Bone Marrow from Unrelated Donors: Bone Marrow Allografts Have Improved Long-Term Overall and Graft-versus-Host Disease-Free, Relapse-Free Survival. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 270-278.	2.0	21
132	Comparison of HLA Allele Mismatch and Antigen Mismatch in Unrelated Bone Marrow Transplantation in Patients with Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 436-442.	2.0	7
133	Difference in the Donor Selection Priority in Allogeneic Hematopoietic Stem Cell Transplantation According to Patient Age. <i>Blood</i> , 2019, 134, 46-46.	1.4	0
134	Allogeneic Hematopoietic Stem Cell Transplantation for Patients with Aggressive Natural Killer Cell Leukemia: An Advantage of Cord Blood Transplantation. <i>Blood</i> , 2019, 134, 2032-2032.	1.4	0
135	Establishment of a Predictive Model of CvHD-Free, Relapse-Free Survival after Allogeneic Hematopoietic Stem Cell Transplantation Using a Machine Learning Algorithm. <i>Blood</i> , 2019, 134, 3337-3337.	1.4	1
136	Impact of Different Doses of Fludarabine in Fludarabine-Based Conditioning Regimen for Unrelated Bone Marrow Transplantation. <i>Blood</i> , 2019, 134, 3258-3258.	1.4	0
137	The Presence of Minimal Residual Disease, As Determined By Highly Sensitive Quantitation of NPM1-Mutation, Provided Powerful Prognostic Information in Acute Myeloid Leukemia. <i>Blood</i> , 2019, 134, 5097-5097.	1.4	0
138	Impact of HLA Class I Allele Mismatch on Viral Infection within 100 Days after Cord Blood Transplantation. <i>Blood</i> , 2019, 134, 3267-3267.	1.4	0
139	Homozygous HLA-C1 is Associated with Reduced Risk of Relapse after HLA-Matched Transplantation in Patients with Myeloid Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 717-725.	2.0	21
140	Deferasirox for the treatment of iron overload after allogeneic hematopoietic cell transplantation: multicenter phase I study (KSGCT1302). <i>International Journal of Hematology</i> , 2018, 107, 578-585.	1.6	6
141	Impact of HIV Infection on Transplant Outcomes after Autologous Peripheral Blood Stem Cell Transplantation: A Retrospective Study of Japanese Registry Data. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 1596-1601.	2.0	5
142	Targeting complete response with upfront bortezomib consolidation versus observation after the achievement of complete response following autologous transplantation for multiple myeloma (TUBA) Tj ETQq0 0 0.7gBT /Overlock 10 T	0.7	0
143	Impact of estimated glomerular filtration rate based on plasma cystatin C and serum creatinine levels before allogeneic hematopoietic cell transplantation. <i>Hematology</i> , 2018, 23, 271-276.	1.5	4
144	Safety of avoiding systemic corticosteroid administration for grade II acute graft-versus-host disease limited to the skin. <i>Annals of Hematology</i> , 2018, 97, 169-179.	1.8	5

#	ARTICLE	IF	CITATIONS
145	Prognostic impact of low allelic ratio FLT3-ITD and NPM1 mutation in acute myeloid leukemia. Blood Advances, 2018, 2, 2744-2754.	5.2	106
146	Successful engraftment after cord blood transplantation from an HLA-homozygous donor (homo-to-hetero cord blood transplantation) in a primary myelofibrosis patient with broad HLA antibodies. Transfusion, 2018, 58, 2773-2776.	1.6	1
147	Allogeneic haematopoietic cell transplantation for adult acute myeloid leukaemia in second remission: a retrospective study of the Adult Acute Myeloid Leukaemia Working Group of the Japan Society for Haematopoietic Cell Transplantation (<sc>JSHCT</sc>). British Journal of Haematology, 2018, 182, 245-250.	2.5	2
148	Impact of the Use and Type of Antibiotics on Acute Graft-versus-Host Disease. Biology of Blood and Marrow Transplantation, 2018, 24, 2178-2183.	2.0	28
149	Adverse Events Associated With Infusion of Hematopoietic Stem Cell Products: A Prospective and Multicenter Surveillance Study. Transfusion Medicine Reviews, 2018, 32, 186-194.	2.0	34
150	Who Is the Best Donor for the Second Transplant?: HLA Discrepancy between Graft and Host Rather Than That Graft and First Donor May Impact the Second Transplant Outcome from the JSHCT. Blood, 2018, 132, 4635-4635.	1.4	1
151	Effect of HLA matching on outcomes in allogeneic stem cell transplantation. Major Histocompatibility Complex, 2018, 25, 112-119.	0.1	0
152	Would Bone Marrow be Associated with Superior Outcomes Compared with Peripheral Blood for Male Recipients with Female Donors in HLA-Matched Related Transplantation?. Blood, 2018, 132, 4669-4669.	1.4	0
153	Effect of Haplotype Matching on Outcomes after Adult Single Cord Blood Transplantation. Blood, 2018, 132, 3461-3461.	1.4	0
154	Phase II Trial of Bortezomib-Based Induction, Autologous Stem Cell Transplantation, Bortezomib-Based Consolidation, and Bortezomib Maintenance in Newly Diagnosed Multiple Myeloma in Japan. Blood, 2018, 132, 3305-3305.	1.4	0
155	Clinical Analysis of Immunodeficiency-Associated Lymphoproliferative Disorders in a Single Institution. Blood, 2018, 132, 5398-5398.	1.4	0
156	A Prospective, Multicenter Surveillance Study for Adverse Events Associated with Hematopoietic Stem Cell Infusion: Analysis of Pediatric and Low Body-Weight Recipients. Blood, 2018, 132, 2105-2105.	1.4	0
157	Clinical characteristics and predictive factors for mortality in coryneform bacteria bloodstream infection in hematological patients. Journal of Infection and Chemotherapy, 2017, 23, 148-153.	1.7	14
158	Meta-analysis of treatment with rabbit and horse antithymocyte globulin for aplastic anemia. International Journal of Hematology, 2017, 105, 578-586.	1.6	25
159	Comparison of levofloxacin and garenoxacin for antibacterial prophylaxis during neutropenia. International Journal of Hematology, 2017, 105, 835-840.	1.6	1
160	Acyclovir-resistant herpes simplex virus 1 infection early after allogeneic hematopoietic stem cell transplantation with T-cell depletion. Journal of Infection and Chemotherapy, 2017, 23, 485-487.	1.7	13
161	HLA-mismatched haploidentical transplantation using low-dose anti-thymocyte globulin (ATG): Tj ETQq1 1 0.784314 rgBT / Overlock 10	1.5	12
162	GvHD prophylaxis after single-unit reduced intensity conditioning cord blood transplantation in adults with acute leukemia. Bone Marrow Transplantation, 2017, 52, 1261-1267.	2.4	39

#	ARTICLE	IF	CITATIONS
163	High pretransplant hepcidin levels are associated with poor overall survival and delayed platelet engraftment after allogeneic hematopoietic stem cell transplantation. <i>Cancer Medicine</i> , 2017, 6, 120-128.	2.8	12
164	Impact of the presence of HLA 1-locus mismatch and the use of low-dose antithymocyte globulin in unrelated bone marrow transplantation. <i>Bone Marrow Transplantation</i> , 2017, 52, 1390-1398.	2.4	23
165	D816 mutation of the KIT gene in core binding factor acute myeloid leukemia is associated with poorer prognosis than other KIT gene mutations. <i>Annals of Hematology</i> , 2017, 96, 1641-1652.	1.8	37
166	Positive Cytotoxic Crossmatch Predicts Delayed Neutrophil Engraftment in Allogeneic Hematopoietic Cell Transplantation from HLA-Mismatched Related Donors. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 1895-1902.	2.0	2
167	Role of reduced-intensity conditioning allogeneic hematopoietic cell transplantation in older patients with de novo acute myeloid leukemia. <i>Annals of Hematology</i> , 2017, 96, 289-297.	1.8	10
168	Impact of Human Leukocyte Antigen Allele Mismatch in Unrelated Bone Marrow Transplantation with Reduced-Intensity Conditioning Regimen. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 300-309.	2.0	12
169	Impact of graft-versus-host disease on outcomes after unrelated cord blood transplantation. <i>Leukemia</i> , 2017, 31, 663-668.	7.2	54
170	A Comparison of Outcomes for Cord Blood Transplantation and Unrelated Bone Marrow Transplantation in Adult Aplastic Anemia. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 1836-1843.	2.0	20
171	Comparison of transplant outcomes from matched sibling bone marrow or peripheral blood stem cell and unrelated cord blood in patients 50 years or older. <i>American Journal of Hematology</i> , 2016, 91, E284-92.	4.1	59
172	Unrelated bone marrow transplantation or immediate umbilical cord blood transplantation for patients with acute myeloid leukemia in first complete remission. <i>European Journal of Haematology</i> , 2016, 97, 278-287.	2.2	14
173	Comparison of graft-versus-host disease-free, relapse-free survival according to a variety of graft sources: antithymocyte globulin and single cord blood provide favorable outcomes in some subgroups. <i>Haematologica</i> , 2016, 101, 1592-1602.	3.5	41
174	Decision Analysis of Postremission Therapy in Cytogenetically Intermediate-Risk Acute Myeloid Leukemia: The Impact of FLT3 Internal Tandem Duplication, Nucleophosmin, and CCAAT/Enhancer Binding Protein Alpha. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 1125-1132.	2.0	21
175	Assessment of the ovarian reserve with anti-Müllerian hormone in women who underwent allogeneic hematopoietic stem cell transplantation using reduced-intensity conditioning regimens or myeloablative regimens with ovarian shielding. <i>International Journal of Hematology</i> , 2016, 104, 110-116.	1.6	13
176	Haploidentical and Matched Sibling Donor Hematopoietic Cell Transplantation for Patients with HLA-Homozygous Haplotypes. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 2031-2037.	2.0	5
177	Significance of a positive <i>Clostridium difficile</i> toxin test after hematopoietic stem cell transplantation. <i>Clinical Transplantation</i> , 2016, 30, 703-708.	1.6	12
178	Risk Factors and Impact of Secondary Failure of Platelet Recovery After Allogeneic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 1678-1683.	2.0	33
179	Graft-versus-Host Disease after HLA-Matched Sibling Bone Marrow or Peripheral Blood Stem Cell Transplantation: Comparison of North American Caucasian and Japanese Populations. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 744-751.	2.0	41
180	High Incidence of Afebrile Bloodstream Infection Detected by Surveillance Blood Culture in Patients on Corticosteroid Therapy after Allogeneic Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 371-377.	2.0	19

#	ARTICLE	IF	CITATIONS
181	Comparison of Outcomes of 8/8 and 7/8 Allele-Matched Unrelated Bone Marrow Transplantation and Single-Unit Cord Blood Transplantation in Adults with Acute Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 330-338.	2.0	100
182	Meta-analysis and meta-regression analysis to compare the outcomes of chemotherapy for T- and B-lineage acute lymphoblastic leukemia (ALL): the use of dexamethasone, l-asparaginase, and/or methotrexate may improve the outcome of T-lineage ALL. <i>Annals of Hematology</i> , 2016, 95, 87-92.	1.8	9
183	Scripts for TRUMP data analyses. Part II (HLA-related data): statistical analyses specific for hematopoietic stem cell transplantation. <i>International Journal of Hematology</i> , 2016, 103, 11-19.	1.6	132
184	Risk factors and prognosis of hepatic acute GvHD after allogeneic hematopoietic cell transplantation. <i>Bone Marrow Transplantation</i> , 2016, 51, 96-102.	2.4	22
185	Impact of the Presence of HLA 1-Locus Mismatch and the Use of Thymoglobulin in Unrelated Bone Marrow Transplantation. <i>Blood</i> , 2016, 128, 4688-4688.	1.4	0
186	A HAMP promoter bioassay system for identifying chemical compounds that modulate hepcidin expression. <i>Experimental Hematology</i> , 2015, 43, 404-413.e5.	0.4	4
187	Impact of HLA Mismatch Direction on the Outcome of Unrelated Bone Marrow Transplantation: A Retrospective Analysis from the Japan Society for Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 305-311.	2.0	31
188	Impact of conditioning intensity and TBI on acute GVHD after hematopoietic cell transplantation. <i>Bone Marrow Transplantation</i> , 2015, 50, 559-565.	2.4	56
189	False-positive Aspergillus galactomannan and its kinetics in allogeneic hematopoietic stem cell transplantation. <i>Journal of Infection</i> , 2015, 70, 520-540.	3.3	17
190	A retrospective analysis of computed tomography findings in patients with pulmonary complications after allogeneic hematopoietic stem cell transplantation. <i>European Journal of Radiology</i> , 2015, 84, 2663-2670.	2.6	6
191	An AKI biomarker lipocalin 2 in the blood derives from the kidney in renal injury but from neutrophils in normal and infected conditions. <i>Clinical and Experimental Nephrology</i> , 2015, 19, 99-106.	1.6	24
192	The Impact of Donor Age on Outcome after Unrelated Bone Marrow Transplantation: Comparison with Unrelated Cord Blood Transplantation. <i>Blood</i> , 2015, 126, 154-154.	1.4	3
193	Donor selection in hematopoietic stem cell transplantation. <i>Journal of Hematopoietic Cell Transplantation</i> , 2014, 3, 39-48.	0.1	0
194	Decision analysis for donor selection in stem cell transplantation-HLA-8/8 allele-matched unrelated donor vs HLA-1 AG mismatched related donor. <i>Blood Cancer Journal</i> , 2014, 4, e263-e263.	6.2	5
195	Prediction of infectious complications by the combination of plasma procalcitonin level and localized infection before allogeneic hematopoietic cell transplantation. <i>Bone Marrow Transplantation</i> , 2014, 49, 553-560.	2.4	8
196	Risk factors and organ involvement of chronic GVHD in Japan. <i>Bone Marrow Transplantation</i> , 2014, 49, 228-235.	2.4	50
197	Single-cell T-cell receptor- β analysis of HLA-A*2402-restricted CMV- pp65-specific cytotoxic T-cells in allogeneic hematopoietic SCT. <i>Bone Marrow Transplantation</i> , 2014, 49, 87-94.	2.4	14
198	Graft-Versus-Host Disease and Survival after Cord Blood Transplantation for Acute Leukemia: A Comparison of Japanese versus White Populations. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 662-667.	2.0	25

#	ARTICLE	IF	CITATIONS
199	Prophylactic role of long-term ultra-low-dose acyclovir for varicella zoster virus disease after allogeneic hematopoietic stem cell transplantation. <i>International Journal of Infectious Diseases</i> , 2014, 19, 26-32.	3.3	39
200	Impact of high-/middle-molecular-weight adiponectin on the synthesis and regulation of extracellular matrix in dermal fibroblasts. <i>Experimental Hematology</i> , 2014, 42, 261-273.	0.4	12
201	Reduced-Intensity Allogeneic Transplantation Using Alemtuzumab from HLA-Matched Related, Unrelated, or Haploidentical Related Donors for Patients with Hematologic Malignancies. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 257-263.	2.0	15
202	Impact of HLA allele mismatch on the clinical outcome in serologically matched related hematopoietic SCT. <i>Bone Marrow Transplantation</i> , 2014, 49, 1187-1192.	2.4	12
203	Antibiotic prophylaxis in hematopoietic stem cell transplantation. A meta-analysis of randomized controlled trials. <i>Journal of Infection</i> , 2014, 69, 13-25.	3.3	57
204	Changes in the Clinical Impact of High-Risk Human Leukocyte Antigen Allele Mismatch Combinations on the Outcome of Unrelated Bone Marrow Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 526-535.	2.0	20
205	Universal cytotoxic activity of a HTLV-1 Tax-specific T cell clone from an HLA-A*24:02+ patient with adult T-cell leukemia against a variety of HTLV-I-infected T-cells. <i>Immunology Letters</i> , 2014, 158, 120-125.	2.5	11
206	Decision Analysis of Allogeneic Hematopoietic Stem Cell Transplantation Versus Chemotherapy in Cytogenetically Standard-Risk Acute Myeloid Leukemia in First Complete Remission: The Impact of FLT3-ITD Profile. <i>Blood</i> , 2014, 124, 1221-1221.	1.4	11
207	Comparison of Outcomes of Unrelated BM and CB Transplants in Young Adult Leukemia Patients. Updated Results of Japanese Registration Study. <i>Blood</i> , 2014, 124, 45-45.	1.4	5
208	Impact of a single human leucocyte antigen (HLA) allele mismatch on the outcome of unrelated bone marrow transplantation over two time periods. A retrospective analysis of 3003 patients from the HLA Working Group of the Japanese Society for Bone Marrow Transplantation. <i>British Journal of Haematology</i> , 2013, 161, 566-577.	2.5	52
209	Effect of HLA mismatch on acute graft-versus-host disease. <i>International Journal of Hematology</i> , 2013, 98, 300-308.	1.6	33
210	Differing impacts of pretransplant serum ferritin and C-reactive protein levels on the incidence of chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. <i>International Journal of Hematology</i> , 2013, 97, 109-116.	1.6	23
211	Decision Analysis of Donor Selection in Allogeneic Stem Cell Transplantation for Patients with Acute Leukemia in First Remission-Related Donor with HLA-1 Antigen Mismatch in the GVH Direction vs. HLA-8/8 Allele-Matched Unrelated Donor. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, S346-S347.	2.0	1
212	Clinical Factors Predicting the Response of Acute Graft-versus-Host Disease to Corticosteroid Therapy: An Analysis from the GVHD Working Group of the Japan Society for Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 1183-1189.	2.0	63
213	Impact of the Direction of HLA Mismatch on Transplantation Outcomes in Single Unrelated Cord Blood Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 247-254.	2.0	46
214	Unrelated cord blood transplantation vs related transplantation with HLA 1-antigen mismatch in the graft-versus-host direction. <i>Leukemia</i> , 2013, 27, 286-294.	7.2	31
215	Prediction of transplant-related complications by C-reactive protein levels before hematopoietic SCT. <i>Bone Marrow Transplantation</i> , 2013, 48, 698-702.	2.4	30
216	Pre-engraftment syndrome after myeloablative dual umbilical cord blood transplantation: risk factors and response to treatment. <i>Bone Marrow Transplantation</i> , 2013, 48, 926-931.	2.4	45

#	ARTICLE	IF	CITATIONS
217	Prediction of infectious events by the high-sensitivity C-reactive protein level before autologous hematopoietic cell transplantation for lymphoma and multiple myeloma. Transplant Infectious Disease, 2013, 15, E169-71.	1.7	3
218	Different effects of HLA disparity on transplant outcomes after single-unit cord blood transplantation between pediatric and adult patients with leukemia. Haematologica, 2013, 98, 814-822.	3.5	77
219	Impact Of Systemic Antibiotic Prophylaxis In Hematopoietic Stem Cell Transplantation Recipients. A Meta-Analysis Of Randomized Controlled Trials. Blood, 2013, 122, 4534-4534.	1.4	0
220	Outcomes of a 1-day nonmyeloablative salvage regimen for patients with primary graft failure after allogeneic hematopoietic cell transplantation. Bone Marrow Transplantation, 2012, 47, 700-705.	2.4	24
221	Impact of graft-versus-host disease on outcomes after allogeneic hematopoietic cell transplantation for adult T-cell leukemia: a retrospective cohort study. Blood, 2012, 119, 2141-2148.	1.4	110
222	Related transplantation with HLA-1 Ag mismatch in the GVH direction and HLA-8/8 allele-matched unrelated transplantation: a nationwide retrospective study. Blood, 2012, 119, 2409-2416.	1.4	57
223	Immune Recovery in Adult Patients after Myeloablative Dual Umbilical Cord Blood, Matched Sibling, and Matched Unrelated Donor Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation, 2012, 18, 1664-1676.e1.	2.0	94
224	Older Age Increases Non-Relapse Mortality in Patients with Grade II-IV Acute Gvhd After Allogeneic Hematopoietic Cell Transplantation: A Retrospective Analysis of the Japanese Trump Database.. Blood, 2012, 120, 3095-3095.	1.4	0
225	Clinical Factors Predicting the Response of Acute Graft-Versus-Host Disease to Corticosteroid Therapy.. Blood, 2012, 120, 3046-3046.	1.4	0
226	Impact of Parental Donor Type On Outcomes After HLA-Matched and HLA-Mismatched T-Cell-Replete Hematopoietic Cell Transplantation for Patients with Leukemia: A Retrospective Cohort Study.. Blood, 2012, 120, 3113-3113.	1.4	0
227	Iron overload and allogeneic hematopoietic stem-cell transplantation. Expert Review of Hematology, 2011, 4, 71-80.	2.2	20
228	Adult Dual Umbilical Cord Blood Transplantation Using Myeloablative Total Body Irradiation (1350) Tj ETQqO 0 0 rgBT /Overlock 10 Tf 50	2.0	32
229	Alemtuzumab for the prevention and treatment of graft-versus-host disease. International Journal of Hematology, 2011, 93, 586-593.	1.6	53
230	Clinical significance of subcategory and severity of chronic graft-versus-host disease evaluated by National Institutes of Health consensus criteria. International Journal of Hematology, 2011, 93, 532-541.	1.6	13
231	Pretransplant serum ferritin and C-reactive protein as predictive factors for early bacterial infection after allogeneic hematopoietic cell transplantation. Bone Marrow Transplantation, 2011, 46, 208-216.	2.4	46
232	Chemo-Mobilization Provides Superior Mobilization and Collection in Autologous Stem Cell Transplants but with Less Predictability and At a Higher Cost,. Blood, 2011, 118, 4048-4048.	1.4	6
233	The Impact of Lymphocyte Subset Recovery At 3 Months on Progression-Free Survival After Myeloablative Allogeneic Stem Cell Transplantation,. Blood, 2011, 118, 4065-4065.	1.4	0
234	Differences in Stem Cell Collection Practices and Related Outcomes Between Centers That Conduct and Do Not Conduct Aphaeresis on Weekends. Blood, 2011, 118, 1925-1925.	1.4	0

#	ARTICLE	IF	CITATIONS
235	The Author's Reply: Sleep Complaints in Hospitalized Italian Patients with Hematological Malignancies. Internal Medicine, 2010, 49, 1691-1691.	0.7	0
236	Haploidentical Transplantation for Leukemia. Current Oncology Reports, 2010, 12, 292-301.	4.0	22
237	Transplantation of allogeneic hematopoietic stem cells for adult T-cell leukemia: a nationwide retrospective study. Blood, 2010, 116, 1369-1376.	1.4	255
238	Impact of discontinuing fluoroquinolone prophylaxis on early mortality after allogeneic marrow or peripheral blood SCT with myeloablative conditioning. Bone Marrow Transplantation, 2010, 45, 1369-1371.	2.4	7
239	Adult Dual Umbilical Cord Blood Transplantation Using Myeloablative Total Body Irradiation (1350cGy) and Fludarabine Conditioning. Blood, 2010, 116, 3523-3523.	1.4	0
240	Prospective, Biological Randomized Study of T-Cell Depleted Nonmyeloablative Allogeneic Transplantation From HLA-Matched Related, Unrelated or Haploidentical Donors for Patients with Hematologic Malignancies. Blood, 2010, 116, 3541-3541.	1.4	0
241	Impact of Serum Ferritin Levels on the Incidence of Chronic Graft-Versus-Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation.. Blood, 2010, 116, 1248-1248.	1.4	1
242	A Comprehensive Comparison Immune Recovery In Adult Patients Following Allogeneic Umbilical Cord Blood, Matched Sibling and Matched Unrelated Donor Stem Cell Transplantation. Blood, 2010, 116, 2313-2313.	1.4	0
243	Mycophenolate mofetil combined with tacrolimus and minidose methotrexate after unrelated donor bone marrow transplantation with reduced-intensity conditioning. International Journal of Hematology, 2009, 89, 538-545.	1.6	8
244	Oncostatin M and leukemia inhibitory factor increase hepcidin expression in hepatoma cell lines. International Journal of Hematology, 2009, 90, 545-552.	1.6	26
245	Impact of ABO mismatching on the outcomes of allogeneic related and unrelated blood and marrow stem cell transplantations for hematologic malignancies: IPDâ€based metaâ€analysis of cohort studies. Transfusion, 2009, 49, 624-635.	1.6	63
246	Clinical Significance of Serum Hepcidin Levels on Early Infectious Complications in Allogeneic Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2009, 15, 956-962.	2.0	22
247	Clinical Significance of Severity and Subcategory of Chronic GVHD Evaluated by NIH Consensus Criteria.. Blood, 2009, 114, 2218-2218.	1.4	0
248	Alcohol Drinking, Smoking, Past History of Gastroduodenal Ulcer, Height, and Risk of API2-MALT1 Fusion Positive and Negative Gastric MALT Lymphoma Among Japanese.. Blood, 2009, 114, 5010-5010.	1.4	0
249	Serum hepcidin level and erythropoietic activity after hematopoietic stem cell transplantation. Haematologica, 2008, 93, 1550-1554.	3.5	57
250	Clinical Significance of Serum Hepcidin-25 Levels on Early Treatment-Related Complications after Hematopoietic Stem Cell Transplantation. Blood, 2008, 112, 1160-1160.	1.4	0
251	Reversible Cardiomyopathy Associated with Multicentric Castleman Disease: Successful Treatment with Tocilizumab, an Anti-Interleukin 6 Receptor Antibody. International Journal of Hematology, 2007, 85, 207-211.	1.6	26
252	Serum Level of Hepcidin and Erythropoietic Activity after Hematopoietic Stem Cell Transplantation.. Blood, 2007, 110, 3000-3000.	1.4	0

#	ARTICLE	IF	CITATIONS
253	Monitoring of Serum Hepcidin-25 in Multicentric Castlemanâ€™s Disease Patients Treated with Tocilizumab, an Anti-Interleukin-6 Receptor Antibody.. Blood, 2007, 110, 3686-3686.	1.4	0